Adalimumab Biosimilar Market Size, Revenue, Forecast Report 2026 to 2035
What is Adalimumab Biosimilar Market Size?
Global Adalimumab Biosimilar Market Size is estimated to grow at the CAGR of 24.6% during the forecast period for 2026 to 2035.
Adalimumab Biosimilar Market Size, Share & Trends Analysis Report By Product (Amjevita, Cyltezo, Hadlima, Yusimry, Hulio, Hymiroz, Abrilada, Yuflyma, Exemptia, Adalirel, Cipleumab and other pipeline products), By Application, By Distribution Channel, By Region, And By Segment Forecasts, 2026 to 2035
Adalimumab Biosimilar Market Key Takeaways:
|
Adalimumab is a human monoclonal antibody that inhibits tumor necrosis factor (TNF), which is a soluble inflammatory cytokine, to treat autoimmune disorders. Adalimumab binds to TNF-alpha (TNF-), blocking it from activating TNF receptors, which are responsible for autoimmune disorders' inflammatory responses. Adalimumab treats rheumatoid, juvenile idiopathic, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. These can be treated with several biosimilars that have been approved by the EMA (European Medicines Agency) and the Food and Drug Administration (FDA) of the United States (U.S.). About 240 biosimilar candidates are being made for all diseases. The Adalimumab Biosimilar market keeps growing due to more strategic partnerships and acquisitions. Biosimilars also bring down the cost of treatment, which helps patients get the care they need.
It was first discovered by the "phage display" technique which was named 'D2E7'. Furthermore, it experienced the various manufacturing process at BASF Bioresearch Corporation and developed by BASF Knoll. In December 2000, Abbott announced the acquisition of BASF Bioresearch Corporation.
Abbott Laboratories spun off its pharmaceutical division, AbbVie Inc., in January 2013. AbbVie sold Adalimumab under the brand name Humira. The FDA and European Medicines Agency authorised it in 2008 and 2003, respectively. Humira's patent expired in June 2017 in Europe and November 2017 in the US. Biosimilar adalimumab products are being developed by numerous pharmaceutical companies because it is the world's best-selling medicine.
The market for biosimilar adalimumab is anticipated to expand at a high rate throughout the forecast period. Adalimumab is one of the top-selling medications in the world. In addition, the entry of adalimumab biosimilar competitors into the market is anticipated to stimulate the expansion of the worldwide adalimumab biosimilar market. The market for biosimilar Adalimumab continues to expand due to additional strategic collaborations and acquisitions. Biosimilars also reduce the cost of treatment, enabling patients to receive the care they require. During the projected period, the market for biosimilar adalimumab will be propelled by the rising demand for biosimilar pharmaceuticals and the rising demand for cost-effective therapy in low- and middle-income nations.
However, the complex regulatory process for the licencing of biosimilars is the key factor impeding the expansion of the adalimumab biosimilars market. In addition, the measures employed by patent holder businesses to combat biosimilar competition hinder the expansion of the adalimumab biosimilar industry. For example, Abbvie filed a complaint against Boehringer Ingelheim about a biosimilar Humira product.
Market Segmentation
The Adalimuman biosimilar market is segmented into three main segments Brand, Product, application and distribution channels. The Brand segment is segmented into Abrilada, Adalirel, Amjevita, Cipleumab, Cyltezo, Exemptia, Hadlima, Hulio, Hymiroz, Idacio, Yuflyma, Yusimry, Simlandi, and others (including products approved in developing countries and pipeline products). The Product segment has Amjevita, Cyltezo, Hadlima, Yusimry, Hulio, Hymiroz, Abrilada, Exemptia, Adalirel, Cipleumab. Based on application, the global adalimumab biosimilar market is segmented into rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, ulcerative colitis, and psoriasis. The rheumatoid arthritis application segment is expected to grow at a higher pace during the forecast period owing to the increasing incidence and prevalence rate of disease across the globe. Based on distribution channels, the global adalimumab biosimilar market is segmented as hospital pharmacies, online pharmacies and other direct distribution channels.
Competitive Landscape
Some Major Key Players In The Adalimumab Biosimilar Market:
- Alvotech
- Amgen Inc.
- Biocon
- Biosimilar Collaborations Ireland Limited
- Boeheringer Ingelheim
- Celltrion, Inc.
- Coherus Biosciences
- Cordavis Ltd.
- Fresenius Kabi
- Glenmark Pharmaceuticals
- Hetero
- Innovent Biologics
- Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics)
- Mylan
- Mylan Pharmaceuticals Inc.
- Organon & Co.
- Organon/Samsung Bioepis
- Pfizer
- Samsung Bioepis
- Sandoz
- Stada Arzneimittel AG
- Synermore
- Teva
- Torrent Pharmaceuticals
- Zydus Cadila
- Other prominent players
Adalimumab Biosimilar Market Report Scope :
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 24.6% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Mn and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product, Application, Distribution Channel |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Amgen, Pfizer, Celltrion Healthcare Co., Ltd., Sandoz International GmbH, LG Life Sciences, Mochida Pharmaceutical, Fresenius Kabi, Kyowa Hakko Kirin, and Momenta Pharmaceuticals, BIOCND, Baxalta (Shire), Organon, Teva, Bio-Thera Solutions, Biocad, Boehringer Ingelheim, CinnaGen, Coherus Biosciences, Hetero Drugs, Hisun Pharmaceuticals, Innovent Biologics, Neuclone, Outlook Therapeutics, Prestige Biopharma,Reliance Life Sciences, Samsung Bioepis, Shanghai Henlius Biotech, Shanghai Junshi Biosciences, Torrent Pharmaceuticals, Zydus Cadila, Kashiv BioSciences, LLC, Hospira Inc., Mylan Pharmaceuticals Inc., Amneal Pharmaceuticals, Inc., and others. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Adalimumab Biosimilar Market Segmentation
Global Adalimumab Biosimilar Market, by Product
- Abrilada
- Adalirel
- Amjevita
- Cipleumab
- Cyltezo
- Exemptia
- Hadlima
- Hulio
- Hymiroz
- Idacio
- Yuflyma
- Yusimry
- Simlandi
- Others (Products approved in developing countries & pipeline products)
Global Adalimumab Biosimilar Market, by Application
- Rheumatoid Arthritis
- Juvenile Idiopathic Arthritis
- Psoriatic Arthritis
- Crohn’s Disease
- Ankylosing Spondylitis
- Ulcerative Colitis
- Psoriasis
Global Adalimumab Biosimilar Market, by Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Other Direct Distribution Channels
Global Adalimumab Biosimilar Market, by Region
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Adalimumab Biosimilar Market Size is estimated to grow at the CAGR of 24.6% during the forecast period for 2026 to 2035.
Amgen, Pfizer, Celltrion Healthcare Co., Ltd., Sandoz International GmbH, LG Life Sciences, Mochida Pharmaceutical, Fresenius Kabi, Kyowa Hakko Kirin,
Adalimuman biosimilar market is segmented into three main segments Brand, Product, application and distribution channels. Yusimry, Simlandi, and others (including products approved in developing countries and pipeline products).
North America region is leading the Adalimumab Biosimilar Market.